Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Brentuximab vedotin - ODMS; Etoposide, Cisplatin, Cytarabine - N/A

Citation

Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP), 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6527/530_v2a_Brentuximab_ESHAP.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Cisplatin, Cytarabine, Etoposide